Drug Trial Radar · NCT07773727
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 5, 2026
Primary completion
Oct 29, 2029
Study completion Feb 18, 2030
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN. While in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise. The study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.
Conditions
- Immunoglobulin A Nephropathy (IgAN)
Interventions
ARGX-121Biological
Subcutaneous Injection of ARGX-121
PlaceboBiological
Subcutaneous Injection of Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in proteinuria from baseline to week 24 as measured by the log-transformed urine protein-to-creatinine ratio (UPCR) derived from 24-h urine collection.Time frame: Up to 24 weeks
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Amicis Research Center - Valencia
Valencia, California · Recruiting
Bioresearch Partners
Miami, Florida · Recruiting
Nephrology Associates of South Miami PA
Miami, Florida · Recruiting
BioResearch Partner - Pembroke Pines
Pembroke Pines, Florida · Recruiting
Michigan Kidney Consultants
Pontiac, Michigan · Recruiting
Prolato Clinical Research Center
Houston, Texas · Recruiting
Northwest Houston Arthritis Center - Houston
Houston, Texas · Not yet recruiting
Utah Kidney Research Institute
Salt Lake City, Utah · Recruiting
Kidney and Hypertension Specialists- Virginia
Manassas, Virginia · Recruiting
Japanese Red Cross Fukuoka Hospital
Fukuoka, Fukuoka, Japan · Recruiting
Sapporo City General Hospital
Sapporo, Hokkaidô, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.